Atypical Hemolytic Uremic Syndrome Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: May 09, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.44 billion |
|
Revenue Forecast in 2031 |
US$ 2.14 billion |
|
CAGR |
4.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Treatment Type, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global atypical hemolytic uremic syndrome treatment market was valued at US$ 1.44 billion in 2022 and is expected to register a revenue CAGR of 4.5% to reach US$ 2.14 billion by 2031.
Atypical Hemolytic Uremic Syndrome Treatment Market Fundamentals
Atypical hemolytic uremic syndrome (aHUS) is a rare and life-threatening disorder that affects the kidneys, blood vessels, and other organs. It is characterized by the formation of small blood clots in the small blood vessels of the body, leading to the destruction of red blood cells, low platelet count, and kidney damage. aHUS are considered "atypical" because it is not caused by an infection with the bacterium Escherichia coli (E. coli), which is the cause of the more common form of the disease known as Shiga toxin-producing E. coli Hemolytic Uremic Syndrome (STEC-HUS). Instead, aHUS is caused by a genetic mutation that affects the complement system, which is a part of the immune system that helps to fight off infections and remove damaged cells from the body. Symptoms of aHUS can include fatigue, weakness, paleness, jaundice, decreased urine output, high blood pressure, and swelling in the legs, feet, or abdomen. In severe cases, aHUS can lead to kidney failure, stroke, heart attack, and other life-threatening complications.
[46456]
Atypical Hemolytic Uremic Syndrome Treatment Market Dynamics
Advances in the understanding of the underlying pathophysiology of aHUS have led to the development of new therapies that target different components of the complement system. This includes drugs that inhibit complement factors such as C5, C3, and Factor B. These new therapies offer promising treatment options for patients with aHUS and boost the overall atypical hemolytic uremic syndrome treatment market. Governments around the world have launched initiatives to support the development of rare disease therapies, including aHUS. This includes regulatory incentives and funding programs that aim to accelerate the development of innovative treatments for rare diseases like aHUS.
Additionally, the limited availability of effective treatments and the high cost of treatment are some of the restraints impeding the overall atypical hemolytic uremic syndrome treatment market growth.
Atypical Hemolytic Uremic Syndrome Treatment Market Ecosystem
Atypical Hemolytic Uremic Syndrome Treatment Market, by Treatment Type
Atypical Hemolytic Uremic Syndrome Treatment Market by Treatment Type
[7564]
The plasma therapy segment dominated the market with the largest revenue share in 2022. Plasma therapy is a type of treatment for atypical hemolytic uremic syndrome that involves replacing deficient proteins in the blood with donor plasma. The goal of plasma therapy is to help control the overactive complement system, which is a key driver of the disease. There are two main types of plasma therapy used in the treatment of aHUS, fresh frozen plasma (FFP) and purified plasma-derived concentrate. FFP is prepared from donated blood and contains a range of proteins, including complement proteins, immunoglobulins, and clotting factors. Purified plasma-derived concentrate is a more targeted approach that involves isolating and purifying specific proteins from donor plasma, such as C1 inhibitor and factor H. Plasma therapy is typically used in combination with other treatments, such as complement inhibitors, to manage the symptoms of aHUS and reduce the risk of complications. Plasma therapy is particularly important in patients who do not respond to complement inhibitors or who have a contraindication to these drugs.
Segmentation of the market refers to the division of the industry into subgroups based on factors such as treatment type. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps in identifying potential atypical hemolytic uremic syndrome treatment market growth opportunities.
Atypical Hemolytic Uremic Syndrome Treatment Market by Region
North America dominated the atypical hemolytic uremic syndrome treatment market with the largest revenue share in 2022, owing to the high prevalence of the disease in the region and the availability of advanced healthcare infrastructure. At present, North America accounts for approximately 42% of the global atypical hemolytic uremic syndrome market. The United States is the largest market for aHUS in North America, and it is also one of the largest markets globally. The country has a high incidence of aHUS, with an estimated prevalence of 2-3 cases per million population. The market for aHUS in the United States is supported by a well-established healthcare infrastructure, with access to advanced diagnostic tools and treatment options. The US FDA has also granted orphan drug designation to several drugs used in the treatment of aHUS, which has encouraged research and development activities in the market.
Based on the regions, the global atypical hemolytic uremic syndrome treatment market is segmented into:
Regional demarcation of the industry will provide information on geographic pockets regarding atypical hemolytic uremic syndrome treatment market outlook, size, share, and growth rate. This data helps businesses evaluate the expansion potential into new regional markets, understand the competitive threats across different regions, and develop localized sales and expansion strategies.
Key Components of the Report
The research study on the atypical hemolytic uremic syndrome treatment market overview thoroughly analyzes the market, along with the aspects that either help or hinder the market's growth, such as its drivers, challenges, and opportunities. The research also discusses the list of businesses that operate in this market and their efforts to establish themselves as major players through expansion plans and innovative ideas. It also emphasizes current events that support the market's revenue expansion. The research also analyses how the COVID-19 pandemic has affected society.
This report is an important tool for the industry stakeholders to gather all the information about the market, customers, and competition. The report also provides the readers with valuable insights on the segmentation, regions, market size & forecast, revenue CAGRs, and other valuable data to help make informed strategic decisions. The study compiles information gathered from industry participants and specialists across the industry value chain. The report also taps into the qualitative and quantitative assessments by industry analysts. Our reports use different methods for estimating the market size and forecast, including secondary research, surveys and interviews, and statistical modeling. With these steps, our reports provide the most accurate market data. These datasets will cumulatively provide in-depth atypical hemolytic uremic syndrome treatment market forecast to the industry stakeholders.
Atypical Hemolytic Uremic Syndrome Treatment Market Competitive Landscape
The market competitive landscape is performed by collecting and analyzing information about the key competitors, the present industry trends, and market dynamics. It includes information collection and analysis on factors such as products, pricing, geographic outreach, customer demographics, marketing strategies, and recent developments. Competitive landscape assessment will help businesses identify the current prevalent or potential opportunities and threats keeping in mind the atypical hemolytic uremic syndrome treatment industry trends.
Atypical Hemolytic Uremic Syndrome Treatment Market Strategic Developments
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Reasons to Buy this Report
Atypical hemolytic uremic syndrome (aHUS) is a rare and life-threatening disorder that affects the kidneys, blood vessels, and other organs.
The global atypical hemolytic uremic syndrome treatment market was valued at US$ 1.44 billion in 2022.
North American region will have the largest atypical hemolytic uremic syndrome treatment market size during the forecast period from 2023 to 2031.
The revenue CAGR of the atypical hemolytic uremic syndrome treatment market during the forecast period will be 4.5% from 2023 to 2031.
Advancements in research is the most prominent localized temperature therapy products industry trend.
The competition from existing treatments and the high cost of treatment are some key challenges hampering the growth of the global atypical hemolytic uremic syndrome treatment market.
Increasing prevalence and government initiatives are growth opportunities in the global atypical hemolytic uremic syndrome treatment market.
Some of the prominent players in the atypical hemolytic uremic syndrome treatment market are Tasly Biopharmaceuticals, Prestige BioPharma, Abbott Laboratories Inc., Teva Pharmaceuticals Ltd., and Zydus Pharmaceuticals, Inc.
The plasma exchange therapy segment has the highest share in the global atypical hemolytic uremic syndrome treatment market.
*Insights on financial performance are subject to the availability of information in the public domain